Stocks

NRX Pharmaceuticals Inc

NRXPNASDAQUSDHealthcare

About NRX Pharmaceuticals Inc

NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder (PTSD), and schizophrenia in the United States. It operates through NRx and Dura segments. The company develops NRX-101, an oral fixed-dose combination of D-cycloserine (DCS) and lurasidone in Phase 2/3 clinical testing for bipolar depression with sub-acute ideation and behavior; NRX-100, a preservative-free formulation of ketamine for intravenous infusion and for the treatment of suicidal depression; and KETAFREE, a generic preservative-free formulation of ketamine. It also provides precision-based interventional psychiatry services to patients with treatment-resistant depression and PTSD using a combination of neuroplastic drugs, transcranial magnetic stimulation (TMS), digital therapeutics, and hyperbaric therapy; ketamine infusion therapy; stellate ganglion blocks; Spravato administration; psychotherapy; and medication management. The company has a development and license agreement with Glytech LLC. NRx Pharmaceuticals, Inc. was founded in 2015 and is headquartered in Wilmington, Delaware.

Ticker
NRXP
Trading on
NASDAQ
ISIN
-
Industry
Biotechnology
Sector
Healthcare
CEO
Dr. Jonathan C. Javitt M.D., M.P.H.
Headquarters
1201 N. Market Street, Wilmington, DE, United States, 19801
Employees
29
Website
nrxpharma.com

Metrics

Market cap$95.6M
P/E ratio-
EPS-$0.58
Dividend Yield0.00%
Beta2.06
Forward P/E ratio34.25
EBIDTA$-19.8M
Ex dividend date-

Analyst Insights & forecasts

Buy100%
Hold0%
Sell0%

Based on information from 3 analysts.

Average price target$48.33

Earnings per share (EPS) forecast

Q3 • 25Q4 • 25Q1 • 26Q2 • 26
Actual-$0.51$0.18-$0.04-$0.18
Expected-$0.02-$0.08-$0.11-$0.09
Surprise-2,450.00%329.13%63.64%-100.00%
MissedBeatBeatCurrent

Financial Performance

Q1 • 26Q2 • 26QoQ growth
Revenue$1.1M$1.1M3.09%
Net income$-1.4M$-16.5M1,055.24%
Profit margin-133.90%-1,500.45%1,020.62%

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

FAQs

01How much is a NRX Pharmaceuticals Inc share?

NRX Pharmaceuticals Inc shares are currently traded for undefined per share.

02How many shares does NRX Pharmaceuticals Inc have?

NRX Pharmaceuticals Inc currently has 43.6M shares.

03Does NRX Pharmaceuticals Inc pay dividends?

No, NRX Pharmaceuticals Inc doesn't pay dividends.

04What is NRX Pharmaceuticals Inc 52 week high?

NRX Pharmaceuticals Inc 52 week high is $5.06.

05What is NRX Pharmaceuticals Inc 52 week low?

NRX Pharmaceuticals Inc 52 week low is $1.62.

06What is the 200-day moving average of NRX Pharmaceuticals Inc?

NRX Pharmaceuticals Inc 200-day moving average is $2.97.

07Who is NRX Pharmaceuticals Inc CEO?

The CEO of NRX Pharmaceuticals Inc is Dr. Jonathan C. Javitt M.D., M.P.H..

08How many employees NRX Pharmaceuticals Inc has?

NRX Pharmaceuticals Inc has 29 employees.

09What is the market cap of NRX Pharmaceuticals Inc?

The market cap of NRX Pharmaceuticals Inc is $95.6M.

10What is the P/E of NRX Pharmaceuticals Inc?

The current P/E of NRX Pharmaceuticals Inc is null.

11What is the EPS of NRX Pharmaceuticals Inc?

The EPS of NRX Pharmaceuticals Inc is -$0.58.

12What is the PEG Ratio of NRX Pharmaceuticals Inc?

The PEG Ratio of NRX Pharmaceuticals Inc is null.

13What do analysts say about NRX Pharmaceuticals Inc?

According to the analysts NRX Pharmaceuticals Inc is considered a buy.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.